Azitra is trading at $0.14, up 5.31%, with no identified company-specific announcement explaining the October 7 move.
- Azitra’s latest reported news was an October 1 trial update.
- The update said the ATR04-484 study could proceed to Cohort 2 after a safety review, but it predates the move and does not establish its cause.
- Broader markets were lower, and the biotech sector was under pressure; neither clearly explains Azitra’s gain.